文献速递妇科

单药曲贝替定治疗经重度治疗的复发性卵巢癌患者

Single agent trabectedin in heavily pretreated patients with recurrent ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2017-07-24

本回顾性研究纳入2012年1月至2015年12月在蒙特利尔大学中心医院接受静脉曲贝替定1.3mg/m2每3周一次的42例复发性卵巢癌患者,评估疗效与耐受性。中位无进展生存期4.3个月(95%CI 3.4-5.1),中位总生存期16.2个月(95%CI 9.0-23.5),耐受性良好。

要点

  • 42例复发性卵巢癌患者接受曲贝替定1.3mg/m2每3周一次静脉给药。
  • 中位无进展生存期4.3个月(95%CI 3.4-5.1),中位总生存期16.2个月(95%CI 9.0-23.5)。
  • 完全缓解19%、部分缓解29%、疾病稳定33%、进展19%,耐受性良好。

核心结论

  • 曲贝替定作为单药在经重度治疗的复发性卵巢癌患者中显示出值得关注的疗效。

研究设计与样本

  • 回顾性研究,纳入2012年1月至2015年12月在蒙特利尔大学中心医院接受静脉曲贝替定1.3mg/m2输注3小时、每3周一次的复发性卵巢癌患者,共42例。
  • 主要结局为基于CA-125水平、临床检查和/或实体瘤疗效评价标准(RECIST)的无进展生存期,同时评估总生存期、缓解率和毒性。

主要发现

  • 患者中位年龄59岁,12%接受二线或三线治疗,43%接受四线或五线治疗,45%接受≥六线治疗,45%为铂耐药。
  • 中位接受周期数为6(范围1-19周期)。
  • 完全缓解、部分缓解、疾病稳定和进展分别占19%、29%、33%和19%。
  • 中位无进展生存期4.3个月(95%CI 3.4-5.1),中位总生存期16.2个月(95%CI 9.0-23.5)。
  • 在获得临床获益(完全缓解、部分缓解、疾病稳定)的患者中,中位无进展生存期为4.6个月。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In 2012, due to a shortage of pegylated liposomal doxorubicin, single agent trabectedin was proposed as an alternative of treatment to our patients with recurrent ovarian cancer (ROC) at our center. The aim of this retrospective study was to evaluate efficacy and tolerability of trabectedin in this context. PATIENTS AND METHODS: This retrospective study included all patients who received intravenous trabectedin 1.3mg/m2 over 3h every 3weeks for ROC between January 2012 and December 2015 at the Centre hospitalier de l'Université de Montreal. The primary outcome was the progression-free survival (PFS) based on CA-125 levels, clinical exam and/or Response Evaluation Criteria in Solid Tumors criteria. We also evaluated overall survival (OS), response rate and toxicities. RESULTS: A total of 42 patients with a median age of 59years received trabectedin in 2nd or 3rd line (12% of patients), 4th or 5th line (43%), and ≥6 lines (45%) and 45% were platinum-resistant. The median number of cycles received was 6 (range 1-19cycles). Complete response (CR), partial response (PR), stable disease (SD) and progression occurred in 19%, 29%, 33% and 19% of patients, respectively. The median PFS and OS was 4.3months (95% CI, 3.4-5.1) and 16.2months (95% CI, 9.0-23.5), respectively. In patients with a clinical benefit (CR, PR, SD), the median PFS was 4.6months. Trabectedin was well tolerated with few adverse events. CONCLUSION: Our results demonstrate that trabectedin has an interesting efficacy as a single agent in heavily treated ROC patients.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Adam JP, Boumedien F, Letarte N, et al. Single agent trabectedin in heavily pretreated patients with recurrent ovarian cancer. Gynecol Oncol. 2017. PMID: 28751117. doi:10.1016/j.ygyno.2017.07.123

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。